BioSpace News Archive

Abilita Bio, Inc., today announced the appointment of Daniel M. Bradbury to its Board of Directors.

AMRA Medical, announced today that AMRA has received 510(k) clearance from the FDA and MDEL (Medical Device Establishment Licence) licensing.

Jupiter Neurosciences, Inc. (“Jupiter” or the “Company”), today announced the completion of its Phase I clinical trial with its proprietary JOTROL™, an enhanced formulation of resveratrol with increased bioavailability.

Urinalysis, or the detection and estimation of various pathophysiological substances in urine samples, is routinely recommended for disease diagnosis.

MilliporeSigma, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2021 financial results prior to market open on Wednesday, March 2, 2022.

Omada Health, a chronic care integrated healthcare provider, announced its $192 million Series E funding round led by Fidelity Management & Research Company with participation from aMoon, existing investorsPerceptive Advisors, Wellington Management, Civilization Ventures, and others.

Parexel, a leading global clinical research organization (CRO), and n-Lorem, a nonprofit foundation, today announced a new partnership in support of n-Lorem’s effort to discover and provide experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1 to 30 patients worldwide) for free, for life.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that the first patient has been enrolled in the Company’s Phase 2 clinical trial of lead candidate MYMD-1, an oral immune regulator drug, as a therapy for delaying aging and expanding healthy lifespan.

Veristat, a scientific-minded global clinical research organization (CRO), announced the appointment of Joe Scott to the position of Chief Financial Officer